Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022
23 Febbraio 2023 - 10:04PM
(NASDAQ: ENOB) -- On February 16, 2023, Enochian BioSciences
Inc. (the "Company") received a notice (the "Notice") from The
Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company
has not yet filed its Form 10-Q for the period ended December 31,
2022 (the "Form 10-Q"), the Company remains in non-compliance with
Nasdaq Listing Rule 5250(c)(1), which requires listed companies to
timely file all required periodic financial reports with the
Securities and Exchange Commission (the "SEC"). As previously
disclosed on Form 8-Ks filed with the Securities and Exchange
Commission, on October 17, 2022 and November 23, 2022,
respectively, the Company received notices from Nasdaq indicating
that as a result of not having timely filed its Annual Report on
Form 10-K for the period ended June 30, 2022 (the "Form 10-K") and
its Quarterly Report on Form 10-Q for the period ended September
30, 2022, the Company was not in compliance with Nasdaq Listing
Rule 5250(c)(1).
This notification has no immediate effect on the
listing of the Company’s shares on Nasdaq. However, if the Company
fails to timely regain compliance with the Nasdaq Listing Rule, the
Company’s common stock will be subject to delisting from
Nasdaq.
As previously reported on Form 8-K, Nasdaq
accepted the Company’s plan to regain compliance with Nasdaq
Listing Rule 5250(c)(1) and therefore the Company has 180 calendar
days from the due date of the Form 10-K, or April 11, 2023, to
regain compliance, and file the Form 10-K and Form 10-Qs for the
periods ended September 30, 2022 and December 31, 2022.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties,
including but not limited to the success or efficacy of our
pipeline. All statements other than historical facts are
forward-looking statements, which can be identified by the use of
forward-looking terminology such as “believes,” “plans,” “expects,”
“aims,” “intends,” “potential,” or similar expressions. Actual
events or results may differ materially from those projected in any
of such statements due to various uncertainties, including as set
forth in Enochian BioSciences’ most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement, and Enochian
BioSciences Inc. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
Source: Enochian Biosciences Inc.
Contact: ir@enochianbio.com
Grafico Azioni Enochian Biosciences (NASDAQ:ENOB)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Enochian Biosciences (NASDAQ:ENOB)
Storico
Da Giu 2023 a Giu 2024